Cytosorbents Corporation Price Chart
Cytosorbents Corporation HQE1.F Financial and Trading Overview
Cytosorbents Corporation stock price | 0.76 EUR |
Previous Close | 3.09 EUR |
Open | 3.1 EUR |
Bid | 3.21 EUR x 160000 |
Ask | 3.32 EUR x 150000 |
Day's Range | 3.21 - 3.21 EUR |
52 Week Range | 0.96 - 3.94 EUR |
Volume | 2K EUR |
Avg. Volume | 64 EUR |
Market Cap | 105.53M EUR |
Beta (5Y Monthly) | 0.70669 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.646 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.6 EUR |
HQE1.F Valuation Measures
Enterprise Value | 136.27M EUR |
Trailing P/E | N/A |
Forward P/E | -45.857143 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.9770865 |
Price/Book (mrq) | 4.863636 |
Enterprise Value/Revenue | 3.844 |
Enterprise Value/EBITDA | -4.439 |
Trading Information
Cytosorbents Corporation Stock Price History
Beta (5Y Monthly) | 0.70669 |
52-Week Change | 76.48% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.94 EUR |
52 Week Low | 0.96 EUR |
50-Day Moving Average | 2.81 EUR |
200-Day Moving Average | 2.22 EUR |
HQE1.F Share Statistics
Avg. Volume (3 month) | 64 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 31.65M |
Float | 37.1M |
Short Ratio | N/A |
% Held by Insiders | 9.29% |
% Held by Institutions | 37.25% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -87.93% |
Operating Margin (ttm) | -89.21% |
Gross Margin | 55.78% |
EBITDA Margin | -86.60% |
Management Effectiveness
Return on Assets (ttm) | -28.086% |
Return on Equity (ttm) | -73.88% |
Income Statement
Revenue (ttm) | 35.45M EUR |
Revenue Per Share (ttm) | 0.81 EUR |
Quarterly Revenue Growth (yoy) | 8.69% |
Gross Profit (ttm) | 20.73M EUR |
EBITDA | -30698652 EUR |
Net Income Avi to Common (ttm) | -31172068 EUR |
Diluted EPS (ttm) | -0.646 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 19.05M EUR |
Total Cash Per Share (mrq) | 0.43 EUR |
Total Debt (mrq) | 18.18M EUR |
Total Debt/Equity (mrq) | 62.8 EUR |
Current Ratio (mrq) | 2.699 |
Book Value Per Share (mrq) | 0.66 |
Cash Flow Statement
Operating Cash Flow (ttm) | -23223324 EUR |
Levered Free Cash Flow (ttm) | -21131176 EUR |
Profile of Cytosorbents Corporation
Country | Germany |
State | NJ |
City | Princeton |
Address | 305 College Road East |
ZIP | 08540 |
Phone | 732 329 8885 |
Website | https://www.cytosorbents.com |
Industry | |
Sector(s) | |
Full Time Employees | 198 |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Q&A For Cytosorbents Corporation Stock
What is a current HQE1.F stock price?
Cytosorbents Corporation HQE1.F stock price today per share is 0.76 EUR.
How to purchase Cytosorbents Corporation stock?
You can buy HQE1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cytosorbents Corporation?
The stock symbol or ticker of Cytosorbents Corporation is HQE1.F.
How many shares does Cytosorbents Corporation have in circulation?
The max supply of Cytosorbents Corporation shares is 32.87M.
What is Cytosorbents Corporation Price to Earnings Ratio (PE Ratio)?
Cytosorbents Corporation PE Ratio is now.
What was Cytosorbents Corporation earnings per share over the trailing 12 months (TTM)?
Cytosorbents Corporation EPS is -0.646 EUR over the trailing 12 months.